华仁药业：盐酸异丙肾上腺素原料药获得上市申请批准通知书

Core Viewpoint - Huanren Pharmaceutical's wholly-owned subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the production and sale of "Isoproterenol Hydrochloride" in the domestic market [1] Group 1 - The approval includes the issuance of a "Chemical Raw Material Drug Listing Application Approval Notice" [1] - The raw material drug has met the relevant technical standards for raw material drug review in the country [1] - This development allows the company to expand its product offerings in the domestic market [1]